



Thursday 25 January 2024

- 09.30 - 10.15 **Registration and welcome with coffee/tea**
- 10.15 - 10.25 **Opening by the chair of the NVED**
- 10.25 - 11.30 **Session I - Genodermatosis: from patient needs to treatment and experimental modeling**
 Session chairs: Michel van Geel (*MUMC+*) and Peter van den Akker (*UMCG*)
1. Eva Korte *UMCG* The patient and parent journey of receiving a diagnosis of epidermolysis bullosa, and beyond – a qualitative study.
 2. Cisse Vermeer *UMCG* ASO-mediated exon skipping in intact human skin pointing towards a treatment for RDEB.
 3. Jaimy Kleijnhout *Radboudumc* mRNA-based CRISPR/Cas9 genome engineering in experimental dermatology: a novel Cas9 delivery strategy.
 4. Jaap van der Velden *MUMC+* L12 linker domain specific variants in KRT10 cause atypical epidermolytic ichthyosis.
 5. Daniela Andrei *UMCG* Epidermal Growth Factor Receptor inhibition leads to cellular phenotype correction of DSP-mutated keratinocytes.
- 11.30 - 12.10 **Guest lecture by dr. Klara Mosterd (*MUMC+*): “Oncodermatology 2.0: non-invasive skin cancer care”**
- 12.10 - 13:10 **Lunch**
- 13.10 - 14.15 **Session II - The skin immune system: from health to disease**
 Session chairs: Marcel Bekken (*AmsterdamUMC*) and Bing Thio (*ErasmusMC*)
6. Marcel Teunissen *AmsterdamUMC* In-depth proteomic analyses of innate lymphoid cell subsets from healthy human skin reveal distinctive phenotypes and functions.
 7. Anne-Lise Strandmoe *UMCG* Analysis of the circulating immune profile in pemphigus vulgaris reveals distinct patterns related to disease state.
 8. Yixin Luo *LUMC* Role of HNRNPK deletion in initiating Cutaneous T-Cell Lymphoma pathogenesis: an inducible knockout mouse model.
 9. Willem Zoutman *LUMC* An in-house developed digital PCR-based method for quantification of DNA methylation biomarkers is valuable for diagnostic challenging early Sézary syndrome patients.
 10. Fenna de Bie *LUMC* Standardization of multi center flow cytometry for the detection of circulating Cutaneous T-Cell Lymphoma cells.
- 14.15 - 15.45 **Poster presentations session I with coffee and tea; selection for poster walks by jury**
 14:15 - 15:00 → **odd poster numbers presenting at poster**
 15:00 - 15:45 → **even poster numbers presenting at poster**
- P1. Celinde Wind (*CHDR*) Clinical validation of non-invasive digital biomarkers for severity scoring in early-stage Mycosis Fungoides compared to CAILS.
 - P2. Jannik Rousel (*CHDR*) The treatment response towards the anti-interleukin-23 inhibitor guselkumab in mild psoriasis patients.
 - P3. Digna de Bruin (*CHDR*) An exploratory single-center, two-part study to characterize cutaneous lupus erythematosus and investigate the effect on an immune challenge by comparing CLE patients with healthy volunteers.
 - P4. Anne van Huijstee (*ErasmusMC*) Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in Hidradenitis Suppurativa.
 - P5. Malak Al-Gawahiri (*Radboudumc*) The current lifestyle of psoriasis patients and their motivation to change.
 - P6. Nikki Henckens (*Radboudumc*) Multi-treatment resistance in biological treatment for psoriasis patients: definitions and implications.
 - P7. Nicholas Schröder (*UMCG*) The C4EB study-Transvamix (10% THC / 5% CBD) to treat chronic pain in epidermolysis bullosa: A protocol for an explorative randomized, placebo controlled, and double blind inter-

vention crossover study.

- P8. Esmé Kamphuis (*UMCG*) Real-world experience of abrocitinib treatment in patients with atopic dermatitis: up to 28-week results from the BioDay registry.
- P9. Reineke Soegiharto (*UMCU*) Time on and determinants of effectiveness of high dose omalizumab in chronic urticaria patients.
- P10. Lisa Paulien van der Rijst (*UMCU*) Multidisciplinary diagnosis and follow-up of comorbid asthma and aeroallergen-specific IgE levels in pediatric atopic dermatitis patients treated with dupilumab.
- P11. Lisa Paulien van der Rijst (*UMCU*) Dupilumab induces a significant decrease of food specific IgE levels in pediatric atopic dermatitis patients.
- P12. Juliette Simons (*UMCU*) Evaluating the diagnostic sensitivity of the pulse-controlled ergometry test for cholinergic urticaria.
- P13. Alex Rooker (*AmsterdamUMC*) The risk of keratinocyte cancer in vitiligo and the potential mechanisms involved.
- P14. Loan Nguyễn (*HMC*) Complication rate and prognostic risk factors after surgical treatment of lentigo maligna (melanoma).
- P15. Shidi Wu (*LUMC*) Identification of industrial compounds targeting both tumor cells and cancer-associated fibroblasts in 3D skin equivalents mimicking melanoma and cutaneous squamous cell carcinoma.
- P16. Tom Wolswijk (*MUMC+*) E-learning for training healthcare professionals to differentiate basal cell carcinoma from non-basal cell carcinoma on optical coherence tomography.
- P17. Emmy Cruts (*MUMC+*) Perineural invasion in cutaneous squamous cell carcinoma: it is not only the size that matters.
- P18. Emmy Cruts (*MUMC+*) Patient reported outcomes in the multidisciplinary treatment of patients with high-risk cutaneous squamous cell carcinoma in the head-neck area: measuring decisional conflict, health-related quality of life and satisfaction with care.
- P19. Mikaella Loizou (*MUMC+*) Desmoplasia, a risk factor for recurrence and metastasis in cutaneous squamous cell carcinoma: interobserver agreement among dermatopathologists.
- P20. Ellen Oyen (*MUMC+*) Prescription and management patterns of actinic keratosis in primary care and the implementation of the "Suspect skin lesions" guideline among general practitioners in the Netherlands.
- P21. Anna Zwanenburg (*NKI*) Imaging in advanced basal cell carcinoma: findings and recommendations.
- P22. Sofie Knipping (*Radboudumc*) Translation and validation of the Dutch version of the Sun Exposure and Protection Index (SEPI).
- P23. Joey Karregat (*AmsterdamUMC*) Skin reactions to biocides in Dutch agricultural workers: an exploration.
- P24. Juliette Bollemeijer (*ErasmusMC*) Lifetime prevalence and associated factors of dermatological itch in the middle-aged and elderly: a population-based cross-sectional study.
- P25. Willemijn Witkam (*ErasmusMC*) Association of air pollutant exposure with acne severity in a multi-ethnic adolescent cohort in Rotterdam, The Netherlands.
- P26. Rosanne Ottevanger (*LUMC*) Associated malignancies in patients with mycosis fungoides: a Dutch nationwide retrospective cohort study.
- P27. Juliette Kersten (*LUMC*) Lesional BSA cutoffs and prognosis in early stage Mycosis Fungoides: a retrospective analysis.
- P28. Liana Barenbrug (*Radboudumc*) Explaining the difference in drug survival of biologics between female and male psoriasis patients.
- P29. Leis Beciri (*MUMC+*) Beyond the skin: prevalence of joint complaints in non-syndromic congenital ichthyosis.
- P30. Emma Holtappels (*AmsterdamUMC*) The expression and function of JAK3 and TEC family kinases in the pathogenesis of vitiligo.
- P31. Veerle Merkus (*LUMC*) The development of an immune landscape panel for imaging mass cytometry (IMC) for Cutaneous T cell Lymphoma's (CTCL) patients.
- P32. Noor van Hout (*Radboudumc*) Expanding the possibilities of the stratum corneum model for bacterial growth.
- P33. Marjolein Hiel (*UMCG*) Phenotype switching in relapsed pemphigus patients after rituximab treatment: a single centre retrospective cohort study.
- P34. Josefien van Leengoed (*UMCG*) VEXAS syndrome as an underlying cause of disease in patients with Sweet syndrome: a retrospective cohort study.
- P35. Emily Kallen (*UMCU*) Ana o 3: better prediction of cashew nut allergy than cashew nut extract in adults.
- P36. Lian van der Gang (*UMCU*) Risk of infections during biologic or JAK inhibitor therapy for atopic dermatitis: results from the BioDay registry.
- P37. Nicoline Post (*AmsterdamUMC*) Consensus on the safety and risks of laser and intense pulse light (IPL) treatments in vitiligo patients, an e-Delphi study.

- P38. Tom Wolswijk (*MUMC+*) Repeatability of radiomics features in optical coherence tomography scans of benign nevi: a prospective test-retest study.
- P39. Eva Korte (*UMCG*) Protocol for the development of core domain sets for epidermolysis bullosa clinical trials: a practical framework for working towards harmonization of outcomes.
- P40. Alexandre Motta (*AmsterdamUMC*) A rapid and easy-to-use system to extract skin interstitial fluid for dermatological research.
- P41. Catherine Mergen (*LACDR*) Stratum corneum ceramide profile differs between lesional and non-lesional skin in patients with Mycosis Fungoides.
- P42. Jonas Jäger (*AmsterdamUMC*) Towards next generation reconstructed human skin: construction of a perfusable vascularized dermis inside a Multi-Organ-Chip.

15.45 - 17.05

Session III - Cell and tissue cultures in experimental dermatology

Session chairs: Abdoel El Ghalbzouri (*LUMC*) and Jeroen Bremer (*UMCG*)

- | | |
|----------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| 11. Alesha Louis <i>LUMC</i> | Dissimilar effect of papillary and reticular fibroblasts on pigmentation. |
| 12. Marcel Vlig <i>ADBC</i> | Antimicrobial activity of supplemented medical-grade honey against <i>Pseudomonas aeruginosa</i> in burn wounds. |
| 13. Britt van der Leeden <i>AmsterdamUMC</i> | Development and characterization of a reconstructed human skin burn wound model. |
| 14. Andrew Morrison <i>AmsterdamUMC</i> | Generation of an organotypic 3D human lymph node model to study skin immune responses. |
| 15. Elisabetta Michielon <i>AmsterdamUMC</i> | An immune competent human melanoma-in-skin model as in vitro tool for testing cell-based therapies. |
| 16. Jasper Koning <i>AmsterdamUMC</i> | Endothelialization of multi-Organ-on-Chips with blood and lymphatic endothelial cells for the generation of immunocompetent skin models. |

17:05 - 17:35

Marcel Jonkman lecture by dr. Ibrahim Korkmaz (*AmsterdamUMC*): "Current clinical challenges and pre-clinical research on burn wound healing"

17.35 - 19.45

Drinks and Dinner

19.45 - 20.30

24th general assembly of the NVED

20.30 - 01.00

PubQuiz and Music

Friday 26 January 2024

09.00 - 10.05

Session IV – Molecular dermatopathology

Session chairs: Remco van Doorn (*LUMC*) and Gilles Diercks (*UMCG*)

- | | |
|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 17. Olivia Steijlen <i>ErasmusMC</i> | Beyond routinely scored histopathology variables in cutaneous squamous cell carcinoma: a nested case-control study. |
| 18. Christos Diamantidis <i>MUMC+</i> | Automated detection and segmentation of superficial basal cell carcinoma on optical coherence tomography. |
| 19. Clara Harrs <i>UMCG</i> | Unravelling the aggressive behaviour of cutaneous squamous cell carcinoma in epidermolysis bullosa: evaluation of SOX2 as a potential prognostic and therapeutic biomarker. |
| 20. Catherine Zhou <i>ErasmusMC</i> | The identification of a prognostic immune landscape for distant metastases in early-stage melanoma: RNA sequencing results from a matched case-control cohort. |
| 21. Wouter Ouwerkerk <i>AmsterdamUMC</i> | Biomarkers measured at start of treatment to predict response to treatment in patients with non-segmental vitiligo. |

10.05 - 11.20

Poster presentations (selected for poster prize) with coffee and tea

11.20 - 12.25

Session V - Towards improved treatment of patients with inflammatory skin diseases

Session chairs: Robert Rissmann (*CHDR*) and Martijn van Doorn (*ErasmusMC*)

22. Sarah Thomas *Radboudumc* Switching to IL-23 inhibitors after ustekinumab failure: evaluating real-world outcomes in psoriasis treatment.
23. Charlotte van Riel *Radboudumc* Baseline characteristics of the BeNeBio study: dose reduction of the newest generations biologics (IL-17 and IL-23 Inhibitors) in psoriasis: a pragmatic, multicenter, randomized, controlled, non-inferiority study.
24. Reineke Soegiharto *UMCU* Real-world omalizumab performance in patients with chronic inducible urticaria: data from the DruSO-CU UCARE study.
25. Lisa Paulien van der Rijst *UMCU* Three-year drug survival of dupilumab, cyclosporine A and methotrexate in a large multicenter cohort of pediatric atopic dermatitis patients.
26. Ellen van den Bogaard *Radboudumc* Next Generation ImmunoDermatology (NGID): From one-size-fits-all to high-tech personalized skin care.

12.25 - 13.25

Lunch

13.25 - 14.05

Guest Lecture by dr. Marjolein De Bruin-Weller (*UMCU*): "New perspectives in Atopic Dermatitis"

14.05 - 15.10

Session VI – Mechanisms of inflammatory skin disease

Session chairs: Ferenc Scheeren (*LUMC*) and Marie Louise Schuttelaar (*UMCG*)

27. Coco Dekkers *UMCU* Adult atopic dermatitis patients with type 2 dominant endotype do not respond better to dupilumab treatment than patients with type 2 non-dominant endotype.
28. Celeste Boesjes *UMCU* Differential dynamics of TARC during JAK-inhibitor therapy compared to biological therapies targeting type 2 inflammation.
29. Fieke Rosenberg *UMCG* Transcriptomics and genomics-guided drug repurposing for the treatment of vesicular hand eczema.
30. Luca Meesters *Radboudumc* Th2 and Th17 driven epidermal pathophysiology in atopic dermatitis.
31. Lisa Pagan *CHDR* The vulvar microbiome in lichen sclerosus and high-grade intraepithelial lesions.

15.10 - 15.25

Awards for best presentation and poster

15.25

Closure

Meeting Location:

Congress hotel 'De Werelt'
Westhofflaan 2
6741 KH Lunteren
Tel: 0318-484641

Accreditation:

The NVDV has awarded 9 points for full participation in this scientific meeting last year; accreditation for 2024 is applied for.

Program committee:

Michel van Geel (*MUMC+*), Ellen van den Bogaard (*Radboudumc*), Gilles Diercks (*UMCG*), Luba Pardo (*ErasmusMC*), Walbert Bakker (*AmsterdamUMC*), Abdoel El-Ghalbzouri (*LUMC*), Daphne Bakker (*UMCU*), Ibrahim Korkmaz (*AmsterdamUMC*)

Jury for presentation prize:

Shidi Wu (*LUMC*), Michel van Geel (*MUMC+*), Jos Smits (*Radboudumc*)

Jury for poster prize:

Jasper Koning (*AmsterdamUMC*), Rindert Venema (*UMCG*), Tessa Niemeyer-van der Kolk (*CHDR*)

NVED board:

Remco van Doorn (president and representative in NVDV 'Commissie Nascholing', *LUMC*), Marcel Bekkenk (secretary, *AmsterdamUMC*), Antoni Gostynski (treasurer, *MUMC+*), Patrick Zeeuwen (coordination abstracts and program, *Radboudumc*), Sue Gibbs (*AmsterdamUMC/ACTA*)